(Q40798040)

23 September 2017

title

Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma (English)

1 reference

23 September 2017

Eishiro Mizukoshi

1

1 reference

23 September 2017

Tatsuya Yamashita

2

1 reference

23 September 2017

Kuniaki Arai

3

1 reference

23 September 2017

Takeshi Terashima

4

1 reference

23 September 2017

Masaaki Kitahara

5

1 reference

23 September 2017

Hidetoshi Nakagawa

6

1 reference

23 September 2017

Noriho Iida

7

1 reference

23 September 2017

Kazumi Fushimi

8

1 reference

23 September 2017

Shuichi Kaneko

9

1 reference

23 September 2017

publication date

15 April 2016

1 reference

Cancer Immunology, Immunotherapy

23 September 2017

published in

1 reference

23 September 2017

volume

65

1 reference

23 September 2017

issue

6

1 reference

23 September 2017

page(s)

715-725

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-016-1837-2

23 September 2017

exact match

0 references

cites work

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Loco-regional treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Chemotherapeutic targeting of cancer-induced immunosuppressive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of survival after radioembolization for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1837-2

10.1007/S00262-016-1837-2

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

23 September 2017

1019007862

0 references

1 reference